AT191 / AbClon - LARVOL DELTA

AbClon expands CAR-T pipeline to treat solid tumor (Korea Biomedical Review) - "AbClon said the company is expanding its CAR-T (chimeric antigen receptor-T) pipelines targeting mesothelin and CD30. CAR T-cell therapy is a form of immunotherapy using specially altered T cells to fight cancer...AT191...targeting disease protein CD19, and AT501, an ovarian cancer therapy targeting HER2. It also has made considerable progress in research and development related to solid tumor CAR-T by, for instance, developing Affibody targeting mesothelin."

Clinical • Gastrointestinal Cancer • Gynecologic Cancers • Hematological Malignancies • Hodgkin Lymphoma • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor